Table 3.
Inhaled Therapy Use in the 12 Months Prior to the Index Date
| Therapy, n (%) | Overall Cohort (N=8224) |
|---|---|
| Documented inhaled medication history | 4370 (53.1) |
| Short-acting onlya | 1922 (23.4) |
| DPI | 36 (0.4) |
| pMDI | 1396 (17.0) |
| SMI | 161 (2.0) |
| Nebulizer | 368 (4.5) |
| Short-acting + maintenancea | 1370 (16.7) |
| DPI | 917 (11.2) |
| pMDI | 1117 (13.6) |
| SMI | 226 (2.7) |
| Nebulizer | 2 (0) |
| Maintenance onlya | 1078 (13.1) |
| DPI | 734 (8.9) |
| pMDI | 299 (3.6) |
| SMI | 142 (1.7) |
| Nebulizer | 11 (0.1) |
| No documented inhaled medication history | 3854 (46.9) |
Note: aPatients could be counted in more than one inhaler category and may have been prescribed additional inhalers/medications for COPD not captured here.
Abbreviations: DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; SMI, soft mist inhaler.